Aggregated Alpha-synuclein Mediates Dopaminergic Neurotoxicity in Vivo

Overview

Journal J Neurosci

Specialty Neurology

Date 2007 Mar 23

PMID 17376994

Citations 145

Authors

Magali Periquet

Tudor Fulga

Liisa Myllykangas

Michael G Schlossmacher

Mel B Feany

Affiliations

Soon will be listed here.

Abstract

Mutations in the synaptic protein alpha-synuclein cause rare genetic forms of Parkinson's disease. Alpha-synuclein is thought to play a critical role in more common sporadic cases of Parkinson's disease as well because the protein aggregates in the hallmark intraneuronal inclusions of the disorder, Lewy bodies. To test the role of protein aggregation in the pathogenesis of Parkinson's disease, we expressed a form of alpha-synuclein with a deletion of amino acids 71-82 that is unable to aggregate in vitro in a transgenic Drosophila model of the disorder. We found no evidence of large aggregates or oligomeric species of alpha-synuclein in these animals and no loss of tyrosine hydroxylase-positive neurons. We also expressed a truncated form of alpha-synuclein that has enhanced ability to aggregate in vitro. This truncated form of alpha-synuclein showed increased aggregation into large inclusions bodies, increased accumulation of high molecular weight alpha-synuclein species, and demonstrated enhanced neurotoxicity in vivo. Our findings thus support a critical role for aggregation of alpha-synuclein in mediating toxicity to dopaminergic neurons in vivo, although the precise role each aggregated form of alpha-synuclein plays in neurotoxicity remains to be determined.

Citing Articles

The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.

ODay D Int J Mol Sci. 2025; 25(24.

PMID: 39769187 PMC: 11678063. DOI: 10.3390/ijms252413424.

Non-enzymatic posttranslational protein modifications in protein aggregation and neurodegenerative diseases.

Baldensperger T, Preissler M, Becker C RSC Chem Biol. 2024; 6(2):129-149.

PMID: 39722676 PMC: 11667106. DOI: 10.1039/d4cb00221k.

α-Synuclein pathology as a target in neurodegenerative diseases.

Park H, Kam T, Dawson V, Dawson T Nat Rev Neurol. 2024; 21(1):32-47.

PMID: 39609631 DOI: 10.1038/s41582-024-01043-w.

Exploring the Potential of Biomimetic Peptides in Targeting Fibrillar and Filamentous Alpha-Synuclein-An In Silico and Experimental Approach to Parkinson's Disease.

Frantzeskos S, Biggs M, Banerjee I Biomimetics (Basel). 2024; 9(11).

PMID: 39590277 PMC: 11591946. DOI: 10.3390/biomimetics9110705.

Role of Lipids in the Pathogenesis of Parkinson's Disease.

Kamano S, Ozawa D, Ikenaka K, Nagai Y Int J Mol Sci. 2024; 25(16).

PMID: 39201619 PMC: 11354291. DOI: 10.3390/ijms25168935.

References

Giasson B, Uryu K, Trojanowski J, Lee V . Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem. 1999; 274(12):7619-22. DOI: 10.1074/jbc.274.12.7619. View

Narhi L, Wood S, Steavenson S, Jiang Y, Wu G, Anafi D . Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem. 1999; 274(14):9843-6. DOI: 10.1074/jbc.274.14.9843. View

Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J . alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci. 1999; 19(14):5782-91. PMC: 6783081. View

Conway K, Lee S, Rochet J, Ding T, Williamson R, Lansbury Jr P . Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000; 97(2):571-6. PMC: 15371. DOI: 10.1073/pnas.97.2.571. View

Li H, Chaney S, ROBERTS I, Forte M, Hirsh J . Ectopic G-protein expression in dopamine and serotonin neurons blocks cocaine sensitization in Drosophila melanogaster. Curr Biol. 2000; 10(4):211-4. DOI: 10.1016/s0960-9822(00)00340-7. View

Feany M, Bender W . A Drosophila model of Parkinson's disease. Nature. 2000; 404(6776):394-8. DOI: 10.1038/35006074. View

Serpell L, Berriman J, Jakes R, Goedert M, Crowther R . Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A. 2000; 97(9):4897-902. PMC: 18329. DOI: 10.1073/pnas.97.9.4897. View

Jo E, McLaurin J, Yip C, St George-Hyslop P, Fraser P . alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem. 2000; 275(44):34328-34. DOI: 10.1074/jbc.M004345200. View

Biere A, Wood S, Wypych J, Steavenson S, Jiang Y, Anafi D . Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J Biol Chem. 2000; 275(44):34574-9. DOI: 10.1074/jbc.M005514200. View

10.

Giasson B, Murray I, Trojanowski J, Lee V . A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem. 2000; 276(4):2380-6. DOI: 10.1074/jbc.M008919200. View

11.

Giasson B, Duda J, Murray I, Chen Q, Souza J, Hurtig H . Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000; 290(5493):985-9. DOI: 10.1126/science.290.5493.985. View

12.

Campbell B, McLean C, Culvenor J, Gai W, Blumbergs P, Jakala P . The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem. 2001; 76(1):87-96. DOI: 10.1046/j.1471-4159.2001.00021.x. View

13.

Trojanowski J, Lee V . "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann N Y Acad Sci. 2001; 924:62-7. DOI: 10.1111/j.1749-6632.2000.tb05561.x. View

14.

Bodles A, Guthrie D, Greer B, Irvine G . Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J Neurochem. 2001; 78(2):384-95. DOI: 10.1046/j.1471-4159.2001.00408.x. View

15.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

16.

Auluck P, Chan H, Trojanowski J, Lee V, Bonini N . Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002; 295(5556):865-8. DOI: 10.1126/science.1067389. View

17.

Perez R, Waymire J, Lin E, Liu J, Guo F, Zigmond M . A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci. 2002; 22(8):3090-9. PMC: 6757524. DOI: 20026307. View

18.

Giasson B, Duda J, Quinn S, Zhang B, Trojanowski J, Lee V . Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002; 34(4):521-33. DOI: 10.1016/s0896-6273(02)00682-7. View

19.

Lee M, Stirling W, Xu Y, Xu X, Qui D, Mandir A . Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A. 2002; 99(13):8968-73. PMC: 124407. DOI: 10.1073/pnas.132197599. View

20.

Li H, Du H, Tang L, Hu J, Hu H . Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation. Biopolymers. 2002; 64(4):221-6. DOI: 10.1002/bip.10179. View